<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9065">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05705960</url>
  </required_header>
  <id_info>
    <org_study_id>CULTIVAR</org_study_id>
    <nct_id>NCT05705960</nct_id>
  </id_info>
  <brief_title>Chestnut Consumption on Modulation of Gut Microbiota and Metabolic Parameters</brief_title>
  <acronym>CULTIVAR</acronym>
  <official_title>The Effect of Chestnut Consumption on Modulation of Gut Microbiota and Metabolic Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Nova de Lisboa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associação Centro de Apoio Tecnológico Agro-Alimentar de Castelo Branco (CATAA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Nova de Lisboa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chestnut tree (Castanea sativa Mill.) is a species widely cultivated in Portugal, which&#xD;
      is a major producer of chestnuts. Nuts are nutritionally interesting, not only because of&#xD;
      their content of vitamins, minerals, and phytochemicals but also of their high fiber content.&#xD;
&#xD;
      Fiber, as it is not digested by humans, has a preponderant role in the intestinal microbiota,&#xD;
      for its maintenance, and, consequently, has an impact on metabolic status.&#xD;
&#xD;
      The inclusion of foods rich in these components, and with extensive local production, can be&#xD;
      an excellent strategy for improving the metabolic parameters of the population.&#xD;
&#xD;
      The main objective of this single group assignment clinical trial is to evaluate the effect&#xD;
      of including roasted chestnuts in the daily diet on the composition and diversity of the&#xD;
      intestinal microbiota. It is also intended to evaluate metabolic parameters to determine the&#xD;
      impact of this intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Gut microbiota characterization</measure>
    <time_frame>14 days</time_frame>
    <description>Difference in Gut microbiota taxonomic characterization, from baseline to the end of intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Gut microbiota diversity</measure>
    <time_frame>14 days</time_frame>
    <description>Difference in Gut microbiota Shannon index, from baseline to the end of intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting glucose</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in fasting glucose, measured in mg/dL, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HOMA-IR</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in HOMA-IR from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total cholesterol</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in total cholesterol, measured in mg/dL, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL cholesterol</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in LDL cholesterol, measured in mg/dL, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in high sensitivity PCR</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in high sensitivity PCR, measured in mg/dL, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in breath H2</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in breath H2, measured in ppm, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in breath CH4</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in breath CH4, measured in ppm, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal butyrate</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in fecal butyrate, measured in M, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal acetate</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in fecal acetate, measured in M, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal ALP</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in fecal ALP, measured in mg/g feces, from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal LPS</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in fecal LPS, measured in EU/mL , from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IL-1b</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in IL1b, measured in pg/mL , from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in TNFa</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in TNFa, measured in pg/mL , from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in adiponectin</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in adiponectin, measured in ng/mL , from baseline to end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in leptin</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in leptin, measured in ng/mL , from baseline to end of intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Diet Habit</condition>
  <arm_group>
    <arm_group_label>Chestnut</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chestnut</intervention_name>
    <description>Daily consumption of roasted chestnut (150g) for 14 days</description>
    <arm_group_label>Chestnut</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian.&#xD;
&#xD;
          -  Filling informed consent.&#xD;
&#xD;
          -  Body mass index (BMI) between 18,5 kg/m2 and 25 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chestnut sensibility.&#xD;
&#xD;
          -  Chestnut daily consumption in the month before the study initiation.&#xD;
&#xD;
          -  Having taken antibiotics within the 6 months prior to beginning the study;&#xD;
&#xD;
          -  Use of pro/prebiotics or fiber as a dietary supplement or any food/molecule that&#xD;
             modifies intestinal transit time 6 weeks before recruitment.&#xD;
&#xD;
          -  Use of laxative 6 weeks before recruitment.&#xD;
&#xD;
          -  Specific dietary regimen (e.g., vegan).&#xD;
&#xD;
          -  Specific nutritional therapy (e.g. high protein).&#xD;
&#xD;
          -  Excessive alcohol consumption.&#xD;
&#xD;
          -  Smoking.&#xD;
&#xD;
          -  Diagnosis of gastrointestinal pathology, hormonal or thyroid pathology, autoimmune&#xD;
             diseases, chronic use of corticosteroids, psychiatric disease or Diabetes Mellitus.&#xD;
&#xD;
          -  Use of proton pump inhibitors, antidiabetic drugs, insulin, or statins.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Participation in another clinical trial within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Faria, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Nova de Lisboa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Faria, PhD</last_name>
    <phone>00351218803033</phone>
    <email>ana.faria@nms.unl.pt</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nova Medical School Universidade Nova de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catarina Rodrigues, Msc</last_name>
    </contact>
    <investigator>
      <last_name>Inês Mota, Bsc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 20, 2023</study_first_submitted>
  <study_first_submitted_qc>January 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>January 20, 2023</last_update_submitted>
  <last_update_submitted_qc>January 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chestnut</keyword>
  <keyword>Gut microbiota diversity</keyword>
  <keyword>Short chain fatty acid</keyword>
  <keyword>Lipid</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

